Država: Nova Zelandija
Jezik: angleščina
Source: Medsafe (Medicines Safety Authority)
Latanoprost 0.05 mg/mL; ;
Actavis New Zealand Limited
Latanoprost 0.05 mg/mL
50 mcg/mL
Eye drops, solution
Active: Latanoprost 0.05 mg/mL Excipient: Benzalkonium chloride Dibasic sodium phosphate dodecahydrate Monobasic sodium phosphate dihydrate Purified water Sodium chloride
Bottle, plastic, blow moulded 5 mL LDPE with LDPE dropper and HDPE screw cap. LDPE tamper-proof twist-off over seal., 2.5 mL
Prescription
Prescription
Neuland Laboratories Limited
Reduction of elevated intraocular pressure in patients with ocular hypertension
Package - Contents - Shelf Life: Bottle, plastic, blow moulded 5 mL LDPE with LDPE dropper and HDPE screw cap. LDPE tamper-proof twist-off over seal. - 2.5 mL - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light 4 weeks opened stored at or below 25°C protect from light
2011-06-01
ARROW – LATANOPROST latanoprost 50 micrograms/ml drops, eye, solution PRESENTATION Each 5mL bottle contains 2.5mL of a clear colourless solution containing latanoprost 50 micrograms/ml (0.005%w/v) for topical ophthalmic use. Also contains the preservative benzalkonium chloride 0.02%w/v. USES PHARMACOKINETICS Latanoprost is an isopropyl ester pro drug which is inactive, but after hydrolysis to the acid of latanoprost, becomes biologically active. The pro drug is well absorbed through the cornea and all drug that enters the aqueous humour is hydrolysed during the passage through the cornea. Studies in man indicate that the peak concentration in the aqueous humour is reached about two hours after topical administration. After topical application in monkeys latanoprost is distributed primarily in the anterior segment, the conjunctivae and the eye lids. Only minute quantities of the drug reach the posterior segment. Following an ocular dose of latanoprost, 45% of latanoprost acid is absorbed systemically, with 90% being bound to plasma proteins. There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver. Following intravenous administration in man, the half life in plasma is 17 minutes. The main metabolites, the 1,2-dinor and 1, 2, 3, 4- tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine. PHARMACODYNAMICS Latanoprost, a selective prostaglandin F 2 analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure by increasing the outflow of aqueous humour. Reduction of the intraocular pressure in man starts about three to four hours after administra Preberite celoten dokument